Novo Nordisk stock: Novo Nordisk sets November 3 results date
Published on 10/23/2026 at 15:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSReporting date November 3, 2026
- Novo Nordisk will release third-quarter results on November 3, 2026.
- Oddo BHF raised its target from DKK 221.00 to DKK 305.00 on October 20, 2026.
- Novo Nordisk stock costs EUR 35.08 at Lang & Schwarz on October 23, 2026 at 3:10 p.m. CEST, 0.20 percent below the Xetra close of October 22, 2026 and 34.39 percent below the 52-week high.
Novo Nordisk is scheduled to release its third-quarter results on November 3, 2026, according to MarketScreener. The appointment gives investors a fixed date for the next major test of the diabetes and obesity-care business. At Lang & Schwarz, the stock was trading at EUR 35.08 on October 23, 2026 at 3:10 p.m. CEST, down 0.20 percent versus the Xetra close of October 22, 2026 at EUR 35.15.
Analyst target reaches DKK 305
Oddo BHF raised its Novo Nordisk target from DKK 221.00 to DKK 305.00 on October 20, 2026, while keeping a Neutral rating, MarketScreener reported. The same report cited 36 analysts, including nine positive, 21 neutral and six negative recommendations. The target revision therefore offers a more constructive valuation signal than the unchanged rating.
Stock stays below its yearly high
The euro price sits EUR 18.38 below the 52-week high of EUR 53.46, a distance of 34.39 percent. The cited German market overview placed the 52-week low at EUR 30.40 and showed the share at EUR 35.10 during its October 23, 2026 update, Boerse Express reported. The Lang & Schwarz quote is 15.37 percent above that low, using the same euro price basis.
Valuation and the next date
MarketScreener listed Novo Nordisk's market capitalization at DKK 1.2 trillion and its next earnings release for November 3, 2026. The company profile identifies Novo Nordisk as a pharmaceutical business focused on diabetes, obesity care and rare diseases. The upcoming report will put the latest operating figures beside the revised analyst target and the stock's 2026 decline.
Price stays near EUR 35
For investors, the key short-term comparison is between the November 3 reporting date and the stock's position well below its yearly high. The analyst target is denominated in Danish kroner, while the German quote remains in euros, so the two figures should not be combined into one return calculation.
Novo Nordisk stock was trading at EUR 35.08 at Lang & Schwarz on October 23, 2026 at 3:10 p.m. CEST, 0.20 percent below the Xetra close of October 22, 2026 at EUR 35.15. The further course of trading is shown by the continuously updated real-time quote of Novo Nordisk stock.
Novo Nordisk stock facts
- Company: Novo Nordisk A/S
- ISIN: DK0062498333
- Ticker: NOVO B
- Primary exchange: Nasdaq Copenhagen
- Price Lang & Schwarz (as of October 23, 2026, 3:10 p.m. CEST): EUR 35.08
- Change versus Xetra close: minus 0.20 percent
- Xetra close (October 22, 2026): EUR 35.15
- Market capitalization: DKK 1.2 trillion (as of October 23, 2026)
- 52-week range: EUR 30.40-53.46 (as of October 23, 2026)
- Sector / Industry: Healthcare / Pharmaceuticals
Market context: Latest market reports.
